Apyx Medical's Stock Price Is About To Have A Liposuction - $3 Price Target (65% Downside) - Apyx Medical Corp (NASDAQ:APYX)
J-Plasma use for dermal resurfacing has nasty side effects and heals very slowly - most cosmetic surgeons we have surveyed will not touch it with a 10-foot pole. The hype surrounding Apyx is predicated on the potential commercialization of its J-Plasma technology for dermal resurfacing, branded by the name of Renuvion. With electrosurgical cautery equipment becoming a commodity, Apyx sold this business in August 2018 to Symmetry Surgical for $97M. While Apyx still derives a minor portion of its revenue as an OEM supplier to Symmetry, its main focus now is on the J-plasma cosmetic surgery technology, also known as Renuvion. On April 30, 2007, Apyx acquired the remaining 50% interest in the joint venture for total consideration of $500K, resulting in the Company having 100% ownership of the J-Plasma technology. For JUMP to sell its 50% interest of J-Plasma to Apyx for only $500K means JUMP valued it in 2007 to be worth only $1M. Since 2007, 12 years ago, when the J-Plasma acquisition was made for $1M, Apyx' management:.